FML FORTE Rx
Generic Name and Formulations:
Fluorometholone 0.25%; oph susp; contains benzalkonium chloride.
Indications for FML FORTE:
Adults and Children:
<2yrs: not recommended. ≥2yrs: 1 drop 2–4 times daily. May give every 4 hours for 1st 24–48hrs. Reevaluate after 2 days.
Fungal, mycobacterial, viral (except herpes zoster), or untreated bacterial infections.
Corneal or scleral thinning. Glaucoma. Monitor for secondary infections and intraocular pressure in prolonged use. Avoid abrupt cessation. May mask or exacerbate infections. Pregnancy (Cat.C). Nursing mothers: not recommended.
Ocular irritation, increased intraocular pressure with possible glaucoma, infrequent optic nerve damage, cataracts, delayed wound healing; systemic hypercorticoidism (rare).
Susp—5mL, 10mL, 15mL; Oint—3.5g; Forte—5mL, 10mL, 15mL
Clinical Pain Advisor Articles
- Opioid Use Disorders: Advances in Pharmacotherapy Provide Long-term Results
- Abuse-Deterrent Opioid Formulations: Barriers to Broader Use
- Women Frequently Prescribed High Doses of Opioids After Vaginal Delivery
- Notifications by PDMPs May Not Effectively Reduce Opioid Misuse
- Medical Cannabis Legalization Associated With Reduced Schedule III Opioid Prescriptions
- Neuropathic Pain Medications
- Higher Buprenorphine Dose May Not Increase Severity of Neonatal Abstinence Syndrome
- Terms Used for Addiction May Be Associated With Explicit, Implicit Bias
- Ketamine Infusions May Be Effective for Refractory Headache
- Physical, Psychosocial Activity May Be Protective Against Development of Chronic Pain in Older Adults
- A Physician's Guide to Incorporating Patient Spirituality in Practice
- FDA Taps Social Media to Identify and Assess Emerging Drug Abuse Threats
- Buffered Lidocaine May Be Superior to Nonbuffered Lidocaine for Inferior Alveolar Nerve Block
- Virtual Reality May Effectively Reduce Sensory, Affective, and Cognitive Pain During Labor
- Marijuana's Uncertain Status: Closing the Gap Between State and Federal Policies